DS
LUMO

David Shaw’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

David Shaw’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,556
Closed -$910K – 3576
2016
Q1 		$910K Buy
5,556
+3,334
+150% +$676K ﹤0.01% 2413
2015
Q4 		$728K Buy
+2,222
New +$723K ﹤0.01% 2852

Other funds holding LUMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

David Shaw's LUMO Position: Q2 2018 in Review

David Shaw sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 4,687 shares — an estimated $306K sold.

David Shaw first reported a position in LUMO in Q4 2013 and held it in 16 quarters. The position peaked at $4.49M in Q1 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

  • David Shaw reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • David Shaw sold 4,687 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $306K.
  • David Shaw first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
  • David Shaw's Lumos Pharma, Inc. Common Stock position peaked at $4.49M in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.